Analysts Anticipate Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Will Announce Earnings of -$0.22 Per Share

Share on StockTwits

Equities research analysts expect Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to report ($0.22) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Corbus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.44) and the highest is $0.22. Corbus Pharmaceuticals posted earnings of ($0.21) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 4.8%. The firm is scheduled to report its next earnings report on Wednesday, August 14th.

On average, analysts expect that Corbus Pharmaceuticals will report full-year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($0.61). For the next year, analysts expect that the business will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.19) to ($0.95). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Corbus Pharmaceuticals.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.45). Corbus Pharmaceuticals had a negative return on equity of 166.99% and a negative net margin of 1,219.36%. The business had revenue of $1.89 million for the quarter, compared to the consensus estimate of $20.97 million.

A number of brokerages have recently commented on CRBP. Cantor Fitzgerald reiterated a “buy” rating and issued a $38.00 price target on shares of Corbus Pharmaceuticals in a research note on Tuesday, March 12th. ValuEngine lowered shares of Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. BidaskClub lowered shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 11th. Zacks Investment Research lowered shares of Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Finally, CIBC began coverage on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 20th. They set an “outperform” rating and a $28.00 price target for the company. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $23.59.

NASDAQ CRBP traded down $0.17 on Wednesday, hitting $6.68. 39,205 shares of the company’s stock were exchanged, compared to its average volume of 740,434. The business has a 50-day moving average price of $7.13. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.17. Corbus Pharmaceuticals has a 52 week low of $4.50 and a 52 week high of $9.11. The company has a market cap of $458.92 million, a PE ratio of -6.81 and a beta of 2.01.

A number of institutional investors have recently bought and sold shares of CRBP. Barclays PLC raised its stake in shares of Corbus Pharmaceuticals by 5,967.8% during the fourth quarter. Barclays PLC now owns 9,041 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 8,892 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Corbus Pharmaceuticals by 72,906.3% during the first quarter. BNP Paribas Arbitrage SA now owns 11,681 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 11,665 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth about $97,000. Cetera Advisor Networks LLC acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth about $98,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in shares of Corbus Pharmaceuticals by 357.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,973 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 13,265 shares in the last quarter. 36.66% of the stock is owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

Further Reading: Bollinger Bands

Get a free copy of the Zacks research report on Corbus Pharmaceuticals (CRBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

TigerLogic Corp.’s  Lock-Up Period Will End Tomorrow
TigerLogic Corp.’s Lock-Up Period Will End Tomorrow
Futu Holdings Ltd  Short Interest Down 9.1% in August
Futu Holdings Ltd Short Interest Down 9.1% in August
Expeditors International of Washington  Short Interest Down 12.2% in August
Expeditors International of Washington Short Interest Down 12.2% in August
Euronet Worldwide, Inc.  Short Interest Update
Euronet Worldwide, Inc. Short Interest Update
Blocktrade  Price Hits $0.0735
Blocktrade Price Hits $0.0735
$63.65 Million in Sales Expected for Opus Bank  This Quarter
$63.65 Million in Sales Expected for Opus Bank This Quarter


 
© 2006-2019 Zolmax.